Le Lézard
Classified in: Health
Subjects: TDS, FVT

Medeor Therapeutics to Present at Cowen Health Care Conference



SAN MATEO, Calif., March 8, 2018 /PRNewswire/ -- Medeor Therapeutics, Inc., a clinical-stage biotechnology company dedicated to the discovery, development and commercialization of personalized cellular immunotherapies, today announced that its President and Chief Executive Officer, Dr. Steven R. Deitcher, will present on Wednesday, March 14th at 1:00 p.m. EST at the Cowen and Company 38th annual Health Care Conference in Boston.

About Medeor Therapeutics, Inc.
Medeor Therapeutics is a clinical-stage biotechnology company dedicated to the discovery, development and commercialization of personalized cellular immunotherapies to improve outcomes in organ transplant recipients as well as non-transplant indications. Medeor's series of product candidates each comprise a unique composition of different types of hematopoietic donor-derived cells, initially based on breakthrough technologies discovered at Stanford University and exclusively licensed by Medeor. These product candidates are designed to produce mixed chimerism, the co-existence of both recipient and donor blood and immune cells in the recipient. For organ transplant recipients, mixed chimerism is intended to allow these patients to achieve donor-specific immune tolerance, prevent transplant organ loss, reduce or eliminate chronic immunosuppressive drug therapy, and thereby improve patient outcomes. For more information, visit www.medeortherapeutics.com.

Contact

Matthew Plunkett, Ph.D.
Chief Financial and Business Officer
mplunkett@medeortherapeutics.com

 

SOURCE Medeor Therapeutics, Inc.


These press releases may also interest you

at 16:30
Champions Oncology, Inc. , engaged in an end-to-end range of research and development technology solutions and services to improve the development and use of oncology drugs, today announced it will report its financial and operational results for the...

at 16:15
Mirati Therapeutics, Inc. , a clinical stage targeted oncology company, today announced the appointment of Maya Martinez-Davis to the Company's Board of Directors, effective immediately. Ms. Martinez-Davis is the President of BioPharma Latin America...

at 16:15
AgraFlora Organics International Inc. (formerly PUF Ventures Inc.) ("AgraFlora" or the "Company") , a growth oriented and diversified international cannabis company is pleased to announce that, further to its news releases dated September 25, 2018,...

at 16:14
HCP, Inc. (the "Company") announced today that it has commenced a public offering of an aggregate of 14,000,000 shares of its common stock, consisting of 2,000,000 shares offered directly by the Company and 12,000,000 shares offered on a forward...

at 16:10
Jazz Pharmaceuticals plc today announced that its Board of Directors has authorized a $400 million increase in the company's share repurchase program, which the company intends to use over time based on market conditions and other factors. Prior to...

at 16:07
Report Scope The increased occurrence of diseases, such as cancer and metabolic diseases, has influenced the pharmaceutical/healthcare industry towards developing efficient and accurate diagnostic tools and therapies.With the increase in the aging...




News published on 8 march 2018 at 16:30 and distributed by: